Collectively, although rhAPE1/Ref-1 or ASA alone did not significantly alter tumor biomarker levels, the combination therapy of rhAPE1/Ref-1 with ASA significantly reduced plasma CEA, CA27-29, and CA15-3 levels. The gene discussed is CEACAM5; the disease is neoplasm.